In the latest quarter, 7 analysts provided ratings for Cigna Group CI, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 7 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 3 | 0 | 0 | 0 |
2M Ago | 0 | 2 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $401.0, a high estimate of $435.00, and a low estimate of $384.00. This current average reflects an increase of 1.13% from the previous average price target of $396.50.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cigna Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Jessica Tassan | Piper Sandler | Announces | Overweight | $400.00 | - |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $400.00 | $400.00 |
Lisa Gill | JP Morgan | Raises | Overweight | $435.00 | $432.00 |
Michael Ha | Baird | Announces | Outperform | $388.00 | - |
Sarah James | Cantor Fitzgerald | Raises | Overweight | $400.00 | $384.00 |
Michael Wiederhorn | Oppenheimer | Raises | Outperform | $400.00 | $370.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $384.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cigna Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cigna Group compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Cigna Group's stock. This analysis reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Cigna Group's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Cigna Group analyst ratings.
About Cigna Group
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.
Key Indicators: Cigna Group's Financial Health
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3 months period, Cigna Group showcased positive performance, achieving a revenue growth rate of 19.28% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.5%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Cigna Group's ROE stands out, surpassing industry averages. With an impressive ROE of -0.63%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Cigna Group's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.18%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Cigna Group's debt-to-equity ratio is below the industry average at 0.8, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.